Compare Neurocrine Biosciences Inc (NBIX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: Neurocrine Biosciences Inc is far larger — about 25.6× Direxion Daily FTSE China Bull 3x Shares's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| NBIX | YINN | |
|---|---|---|
Market Cap | $14.36B | $560.32M |
Volume | 1,237,180 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.50 | $52.69 |
52-Week Low | $123.10 | $21.45 |
Typical Hold Time | 23 Days | 25 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
YINN is trading at $25.27, up 7.26% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed fundamental ratios such as P/E and P/S, and recent news highlights China's economic policies and energy sector dynamics, which may influence its performance. Support is clustered around $23, with resistance at $24.
The outlook remains cautious due to bearish technicals and limited fundamental visibility. Risks include reliance on Chinese economic conditions and potential regulatory changes. Investment opportunities hinge on improved earnings transparency and positive shifts in market sentiment, but current data suggests a neutral to bearish stance for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
